Christina Kackos

Christina Kackos

Auto-generated profile, based on publicly available information

Christina Kackos

Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
AMAllison Murawski
Allison Murawski
TFThomas Fabrizio
Thomas Fabrizio
RORobert J Ossiboff
Robert J Ossiboff
CKChristina Kackos
Christina Kackos
TJTrushar Jeevan
Trushar Jeevan
RWRichard J. Webby
Richard J. Webby
Since late 2021, highly pathogenic avian influenza (HPAI) viruses of A/goose/Guangdong/1/1996 (H5N1) lineage have caused widespread mortality in wild birds and poultry in the United States. Concomitant with the spread of HPAI viruses in birds are increasing numbers of mammalian infections, including wild and captive mesocarnivores and carnivores with central nervous system involvement. Here we report HPAI, A(H5N1) of clade 2.3.4.4b, in a common bottlenose dolphin (Tursiops truncatus) from Florida, United States. Pathological findings include neuronal necrosis and inflammation of the brain and meninges, and quantitative real time RT-PCR reveal the brain carried the highest viral load. Virus isolated from the brain contains a S246N neuraminidase substitution which leads to reduced inhibition by neuraminidase inhibitor oseltamivir. The increased prevalence of A(H5N1) viruses in atypical avian hosts and its cross-species transmission into mammalian species highlights the public health importance of continued disease surveillance and biosecurity protocols.

12 October 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
CKChristina M. Kackos
Christina M. Kackos
JDJennifer DeBeauchamp
Jennifer DeBeauchamp
CDChristopher J. H. Davitt
Christopher J. H. Davitt
JLJan Lonzaric
Jan Lonzaric
RSRobert E. Sealy
Robert E. Sealy
RWRichard J. Webby
Richard J. Webby
Annually, seasonal influenza is responsible for millions of infections and hundreds of thousands of deaths. The current method for managing influenza is vaccination using a standardized amount of the influenza virus’ primary surface antigen, hemagglutinin (HA), as the intended target of the immune response. This vaccination strategy results in vaccines with variable efficacy year to year due to antigenic drift of HA, which can be further exacerbated by manufacturing processes optimizing growth of vaccine virus in eggs. Due to these limitations, alternative vaccine platforms are actively being explored to improve influenza vaccine efficacy, including cell-based, recombinant protein, and mRNA vaccines. mRNA’s rapid, in vitro production makes it an appealing platform for influenza vaccination, and the success of SARS-CoV-2 mRNA vaccines in the clinic has encouraged the development of mRNA vaccines for other pathogens. Here, the immunogenicity and protective efficacy of a quadrivalent mRNA vaccine encoding HA from four seasonal influenza viruses, A/California/07/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (B-Victoria lineage), and B/Phuket/3073/2013 (B-Yamagata lineage), was evaluated. In mice, a 120 μg total dose of this quadrivalent mRNA vaccine induced robust antibody titers against each subtype that were commensurate with titers when each antigen was administered alone. Following A/California/04/2009 challenge, mice were fully protected from morbidity and mortality, even at doses as low as 1 μg of each antigen. Additionally, a single administration of 10 μg of quadrivalent mRNA was sufficient to prevent weight loss caused by A/California/04/2009. These results support the promise of this mRNA vaccine for prevention and mitigation of influenza vaccine.

31 March 2023 in Science Advances
Verified
Journal Article
Closed access
MHMeng Hu
Meng Hu
CKChristina Kackos
Christina Kackos
BBBalaji Banoth
Balaji Banoth
COChet Ojha
Chet Ojha
JJJeremy Jones
Jeremy Jones
CRCharles Russell
Charles Russell
During influenza virus entry, the hemagglutinin (HA) protein binds receptors and causes membrane fusion after endosomal acid activation. To improve vaccine efficiency and pandemic risk assessment for currently-dominant H3N2 influenza viruses, we investigated HA stability of 6 vaccine reference viruses and 42 circulating viruses. Recent vaccine reference viruses had destabilized HA proteins due to egg-adaptive mutation HA1-L194P. Virus growth in cell culture was independent of HA stability. In ferrets, the vaccine reference viruses and circulating viruses required a relatively stable HA (activation and inactivation pH < 5.5) for airborne transmissibility. The recent vaccine reference viruses with destabilized HA proteins had reduced infectivity, had no airborne transmissibility unless reversion to HA1-P194L occurred, and had skewed antigenicity away from the studied viruses and circulating H3N2 viruses. Other vaccine reference viruses with stabilized HAs retained infectivity, transmissibility, and antigenicity. Therefore, HA stabilization should be prioritized over destabilization in vaccine reference virus selection to reduce mismatches between vaccine and circulating viruses.

14 February 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
CKChristina M. Kackos
Christina M. Kackos
SSSherri L. Surman
Sherri L. Surman
BJBart G. Jones
Bart G. Jones
RSRobert E. Sealy
Robert E. Sealy
TJTrushar Jeevan
Trushar Jeevan
RWRichard J. Webby
Richard J. Webby
SARS-CoV-2 continues to disrupt everyday life and cause excess morbidity and mortality worldwide. Vaccination has been key to quelling the impact of this respiratory pathogen, and mRNA vaccines have led the charge on this front.

17 July 2023 in Research Square
Verified
Preprint
Open access
PDF file
AMAllison Murawski
Allison Murawski
TFThomas Fabrizio
Thomas Fabrizio
RORobert J Ossiboff
Robert J Ossiboff
CKChristina Kackos
Christina Kackos
TJTrushar Jeevan
Trushar Jeevan
RWRichard J. Webby
Richard J. Webby
Since late 2021, highly pathogenic avian influenza (HPAI) viruses of the A/goose/Guangdong/1/1996 (H5N1) lineage have continued to cause widespread mortality in wild birds and poultry in the United States. Concomitant with the spread of HPAI viruses in birds are increasing numbers of mammalian infections, including wild and captive mesocarnivores and carnivores with central nervous system involvement. Here we report the first known case of HPAI, A(H5N1) of clade 2.3.4.4b, in a common bottlenose dolphin (Tursiops truncatus) from Florida, United States. Pathological findings included neuronal necrosis and inflammation of the brain and meninges, and quantitative real time RT-PCR revealed the brain carried the highest viral load of tissues tested. Virus isolated from the brain contained a S246N neuraminidase substitution which led to reduced inhibition by the neuraminidase inhibitor oseltamivir. The increased prevalence of A(H5N1) viruses in atypical avian hosts and its cross-species transmission into mammalian species highlights the public health importance of continued disease surveillance and biosecurity protocols.

6 January 2023 in Research Square
Verified
Preprint
Open access
PDF file
PTPaul G Thomas
Paul G Thomas
RMRobert Mettelman
Robert Mettelman
ASAisha Souquette
Aisha Souquette
LVLee-Ann Van De Velde
Lee-Ann Van De Velde
KVKasi Vegesana
Kasi Vegesana
TDTony Dowell
Tony Dowell
Influenza viruses remain a leading cause of global respiratory illness in humans. The suboptimal effectiveness of seasonal influenza vaccination underscores the need for a more comprehensive understanding of immune mediators of protection, especially in populations with diverse baseline immune profiles and exposure histories. While anti-influenza antibody titers are typically used to define correlates of protection, mounting evidence suggests a substantive role for innate and cellular immunity in determining tolerance and resistance during influenza virus infection. However, distinct cell subsets that correlate with protection against symptomatic influenza remain to be identified in humans. Here, we measured baseline cellular and serologic profiles in peripheral blood from 206 vaccinated or unvaccinated adult subjects enrolled in the 2018 SHIVERS-II cohort to determine how baseline variations in the cellular and humoral immune compartments contribute independently or synergistically to the risk of developing symptomatic influenza infection. Protection from symptomatic influenza correlated with increased individual frequencies of diverse and polyfunctional CD4 and CD8 T cells, cells associated with engagement of humoral responses including cTfh and mDCs, Th17 cells, and innate effector CD16-expressing cytotoxic and cytokine-producing NK cells. In contrast, increased susceptibility was predominantly attributed to nonspecific inflammatory populations including γδ T cells and activated CD16neg NK cells, as well as TNFα+ single-producing CD8 T cells. A trained random forest model categorizing symptomatic influenza cases identified that cellular covariates substantially improved model accuracy up to 86% over demographic and serologic factors alone (61%). A corresponding variable importance analysis showed cellular populations comprise 28 of the top 30 covariates (from 48 total), with the single most important factor being ICOS+ cTfh cells. Lastly, using a multivariate logistic regression model considering participant demographics, anti-influenza antibody titers, vaccination status, and cell population covariates, we quantified how these factors contribute to risk of symptomatic influenza infection. Protection was associated with a combination of lymphocyte populations including naïve, CD107a+, and Th17 CD4 T cells, and serologic factors including antibodies targeting neuraminidase. Increased risk of symptomatic influenza (95% subtype A) was associated with elevated anti-hemagglutinin antibodies against influenza B (Yamagata), along with γδ T cells and TNFα+ CD8 T cell single-cytokine producers. Together, these results demonstrate that the composition of pre-infection peripheral cell profiles is a stronger predictor of symptomatic influenza susceptibility than vaccination, demographics, or serology.